Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Actrapid HM · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | 56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily) |
| 2 | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Actrapid HM | DRUG | 56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily) |
Inclusion Criteria: * Sibling/offspring of a Type 1 diabetic patient * in good general condition * age 5-39 years * fasting plasma glucose \<126 mg/dL AND an OGTT that is non-diabetic by 1997 ADA criteria (33): 1. Normal glycemia: * fasting plasma glucose \< 110 mg/dL and * 2 hour pla...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
Actrapid HM is an investigational small molecule being studied for the prevention of clinical onset of Type 1 diabetes in high-risk first-degree relatives. It is being developed by Novo Nordisk A/S (NVO) and is currently in Phase 2 clinical development.
Actrapid HM is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The drug is currently in Phase 2 clinical development for Type 1 diabetes.
Actrapid HM is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed for the prevention of Type 1 diabetes.
Actrapid HM has been studied in one completed Phase 2 clinical trial with the identifier NCT00654121. The trial, titled 'Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives', enrolled 112 participants in Belgium and included healthy volunteers.
Actrapid HM is a small molecule being investigated for the prevention of Type 1 diabetes. The available information does not indicate that it is the same as insulin. Its mechanism of action has not been disclosed in the clinical trial data.